FindTrial
Sign In

Active screening of CRE in patients with hematological diseases and its value in predicting the occurrence of CRE blood flow infection

Active screening of CRE in patients with hematological diseases and its value in predicting the occurrence of CRE blood flow infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016884
Enrollment
Unknown
Registered
2018-06-30
Start date
2018-07-02
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood disease

Interventions

Case series:Nil

Sponsors

Institute of Hematology and Blood Diseases Hospital,CAMS & PUMC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 70 Years

Inclusion criteria

Inclusion criteria: 1. No age limited, both men and women; 2. Blood Diseases, patients receiving immunosuppressive therapy, chemotherapy or hematopoietic stem cell transplantation; 3. Patients or their legal representatives have signed informed consent. They understand the purpose, steps and content of the study and voluntarily participate the clinical trial.

Exclusion criteria

Exclusion criteria: 1. HIV seropositive; 2. Estimated survival time less than 30 days; 3. Patients undergoing other similar clinical trials and whose data are not allowed for use in this trial; 4. Patients with mental or addictive diseases,influence signature of informed consent or treatment with research.

Design outcomes

Primary

MeasureTime frame
Active screening of CRE;—

Countries

China

Contacts

Public ContactHan Mingzhe

Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

mzhan@ihcams.ac.cn+86 13820589867

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026